Last reviewed · How we verify
Anti-TNF Therapy
Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Psoriasis.
At a glance
| Generic name | Anti-TNF Therapy |
|---|---|
| Also known as | Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio |
| Sponsor | Takeda |
| Drug class | TNF inhibitor |
| Target | TNF (Tumor Necrosis Factor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF is a pro-inflammatory cytokine produced by immune cells that promotes inflammation and tissue damage in autoimmune and inflammatory diseases. By neutralizing TNF through monoclonal antibodies or receptor antagonists, anti-TNF therapy suppresses excessive inflammatory responses. This reduces symptoms and prevents progression in conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Juvenile idiopathic arthritis
Common side effects
- Increased infection risk (including tuberculosis)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Malignancy risk (long-term)
- Demyelinating disease
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule (PHASE2)
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (PHASE2)
- Response Assessment in SB CD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-TNF Therapy CI brief — competitive landscape report
- Anti-TNF Therapy updates RSS · CI watch RSS
- Takeda portfolio CI